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a b s t r a c t
Human cytomegalovirus (HCMV) is the leading cause of congenital infections. The aim of our study was
to determine the prevalence of genotypes based on the highly polymorphic UL146 and UL147 HCMV
genes and the relationship between the genotype and symptoms or viral load.
We analyzed samples from 121 infants with symptomatic HCMV infection, including 32 congenitally
infected newborns. The G7 and G5 genotypes were predominant in postnatal infection, whereas the
G1 genotype was prevalent in congenital infection. Central nervous system (CNS) damage and
hepatomegaly were detected more frequently among children infected with the G1 genotype than in
those infected by other genotypes. An association between the viral genotype and viruria level was
found. There was a strong correlation between HCMV genotypes determined through the UL146 and
UL147 sequences (ĸ¼0.794).
In conclusion, we found that certain vCXCL genotypes are associated with clinical sequelae following
HCMV infection.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human cytomegalovirus (HCMV) is an important and wide-
spread pathogen, congenitally infecting 0.3–2.3% of all newborns
(Dollard et al., 2007; Kenneson and Cannon, 2007). Approximately
10–15% of infected newborns are symptomatic and have multi-
system or fatal disease. Symptomatic newborns exhibit central
nervous system (CNS) damage, hepatosplenomegaly, jaundice,
petechiae, hepatitis, intrauterine growth retardation (IUGR), and
thrombocytopenia. The remaining 85–90% of children show no
clinical evidence of infection during the neonatal period, but they
can develop negative clinical outcomes, including hearing loss,
motor deﬁcits, and ocular abnormalities, in subsequent years
(Stagno et al., 1982). Both symptomatic and asymptomatic infants
excrete the virus in their urine and saliva for several years after
birth. The virulence determinants causing congenital or postnatal
HCMV infection and symptomatic disease have yet to be unam-
biguously identiﬁed.
HCMV has a large and complex genome containing more than
200 open reading frames (ORFs), but the genetic variability of
HCMV is limited to distinct parts of the genome (Arav-Boger et al.,
2005, 2006a; Bradley et al., 2008; He et al., 2006; Heo et al., 2008;
Lurain et al., 2006; Pignatelli et al., 2004, 2010). “Key genes”
encoding the envelope glycoproteins (e.g., gB, gN, and gH) and
homologs of cytokine/chemokine receptors, including UL144 and
US28, have been studied due to their potential relevance to cell
tropism and virulence. Although speciﬁc genotypes were detected
in some symptomatic congenital infections, these associations
were unconﬁrmed in functional studies (Barbi et al., 2001;
Pignatelli et al., 2010; Paradowska et al., 2013; Paradowska et al.,
2014; Pati et al., 2013). HCMV also possesses genes that encode
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factors involved in immune evasion, which could function to
increase viral spread and survival (Mocarski, 2002). It encodes a
bona ﬁde CXC chemokine UL146 (vCXCL-1) (Penfold et al., 1999),
CXC chemokine homolog UL147 (vCXCL-2) (Penfold et al., 1999),
CC chemokine homolog UL128 (Akter et al., 2003), and chemokine
receptors. Both the UL146 and UL147 genes are located at the UL/b'
boundary and in 19 ORFs between UL133 and UL151; these genes
are lost after extensive serial passaging of the Towne and AD169
strains in tissue culture (Cha et al., 1996; Prichard et al., 2001).
However, the Towne strain is known to contain a mixture of two
variants, one of which is intact in UL/b0 region (Hahn et al., 2003;
Bradley et al., 2009). UL146 encodes vCXCL-1, an IL-8-like chemo-
kine that is secreted late during infection and induces calcium
mobilization, chemotaxis, and the degranulation of neutrophils
(Penfold et al., 1999). Furthermore, vCXCL-1 appears to be a
determinant of host neutrophil behavior in response to HCMV
infection (Penfold et al., 1999). This glycoprotein functions as a
selective agonist for CXCR1 and CXCR2, although with differing
afﬁnities and potencies (Lüttichau, 2010). vCXCL-2 is not known to
be functional in any assay (Penfold et al., 1999). Although these
genes are not essential for virus replication in vitro, it has been
suggested that they are maintained for infectivity in vivo (Lurain
et al., 2006). Both genes show a high degree of variability in
clinical isolates (Arav-Boger et al., 2005; Bradley et al., 2008; Dolan
et al., 2004; Hassan-Walker et al., 2004; Lurain et al., 2006;
Prichard et al., 2001; Stanton et al., 2005). Moreover, the UL146
gene is one of the most variable genes in the HCMV genome, and
14 genotypes have been cataloged (Arav-Boger et al., 2005; Dolan
et al., 2004; Penfold et al., 1999; Prichard et al., 2001). More
recently, a ﬁfteenth vCXCL-1 genotype was described (Heo et al.,
2008). It has been suggested that HCMV could abate antiviral
immunity by manipulating the host chemokine system and
suppressing the immune system (Bradley et al., 2008). It was
recently found that the UL146 ORF is transcribed with 4 down-
stream ORFs, from UL147 to UL132 (He et al., 2012).
In this study, we determine the prevalence of genotypes based
on the highly polymorphic UL146 and UL147 HCMV genes in
congenitally or postnatally infected infants with symptomatic
infection. The study also addresses whether there is an association
between speciﬁc vCXCL genotypes, viral load, and the presence of
speciﬁc symptoms in HCMV-infected children. All of the examined
infants demonstrated symptomatic HCMV infection at birth or in
the next months of infancy. We studied the UL146 and UL147
genes from the DNA isolates of 32 newborns and 89 infants. While
the gene products were detected in all newborns, we were unable
to amplify them in one-third of the infants. Genotypic analysis of
both genes showed a strong linkage between the vCXCL-1 and
vCXCL-2 genotypes. Moreover, we documented that the HCMV G7
and G5 genotypes were the most prevalent in symptomatic infants
with postnatal or uncharacterized infection, whereas different
genotypes were transmitted from mother to fetus. Our results
suggest that the clinical manifestations of prenatal HCMV trans-
mission are likely to be associated with a high viral load in urine
samples. The certain vCXCL genotypes are associated with clinical
sequelae following HCMV infection during childhood.
Results
Study population and clinical outcome
One hundred twenty-one infants with HCMV infection were
enrolled in the study. The results showed that 32 of them had
congenital HCMV infection that was conﬁrmed by HCMV DNA
detection within the ﬁrst 2–3 weeks of life. Cytomegalovirus
serology assays were performed for 114 of the 121 patients
(94.2%), including 29 newborns with congenital HCMV infection
and 85 postnatally infected infants. The anti-HCMV IgG serology
results were positive for all newborns, whereas 15 of them were
positive for IgG and IgM. Sera from 43 infants were positive for IgG
and IgM, 40 were positive for IgG only, and 2 were IgG and IgM
negative. HCMV DNA was detected in all examined children. The
UL146 and UL147 gene products were successfully ampliﬁed in all
of the examined newborns with congenital infection and in 56 of
89 (62.9%) infants, and the remainder of the analysis was
performed using the patients with successful ampliﬁcation. Addi-
tionally, both genes were detected in all adult patients. In all
subjects, the HCMV UL55 gene was quantiﬁed by real-time PCR.
Symptoms of HCMV infection were determined at birth in all
newborns and when they became evident later in childhood in
infants. The most common ﬁndings were as follows, 63 cases of
hematological disorders, 47 cases of neurological dysfunction,
37 cases of psychomotor retardation, 30 cases of CNS damage,
and 26 cases of jaundice, among others (Table 1). As expected from
many studies, symptoms were detected in newborns more often
than in infants: intracranial calciﬁcation, cystic lesions, IUGR,
hepatomegaly, petechiae/purpura, hearing loss (po0.001); ocular
abnormalities (p¼0.001); thrombocytopenia (p¼0.002); neurolo-
gical dysfunction (p¼0.026); anemia (p¼0.003); microcephaly or
ventriculomegaly (p¼0.004); and splenomegaly (p¼0.007). The
incidence of speciﬁc symptoms was similar in infant groups with
and without successful ampliﬁcation.
Viral load
The number of HCMV DNA copies was determined in urine and
blood samples obtained from children (Fig. 1A and B). The median
HCMV DNA concentration in urine was signiﬁcantly higher
(7.74106 copies/mL; range 0–8.73108 copies/mL) in newborns
with congenital infection than in infants with postnatal HCMV
infection (3.32104 copies/mL; range 0–2.21108 copies/mL),
po0.001 (Mann–Whitney U test) (Fig. 1A). The viremia levels
Table 1
Clinical and laboratory ﬁndings in infants with symptomatic HCMV infection.
Findings No. positive infants (%)
Congenital
infection
Postnatal
infection
p-value
Anemia 28 (87.5) 33 (58.9) 0.003
Thrombocytopenia 12 (37.5) 5 (8.9) 0.002
Other hematological
disordersa
1 (3.1) 9 (16.1) 0.087
Neurological dysfunctionb 22 (68.8) 25 (44.6) 0.026
Microcephaly 8 (25.0) 2 (3.6) 0.004
Intracranial calciﬁcation 14 (43.8) 3 (5.4) o0.001
Ventriculomegaly 8 (25.0) 2 (3.6) 0.004
Cystic lesions 16 (50.0) 6 (10.7) o 0.001
Psychomotor retardation 17 (53.1) 20 (35.7) 0.116
Hearing loss 14 (43.8) 6 (10.7) o0.001
Ocular defects 10 (31.2) 3 (5.4) 0.001
IUGR 14 (43.8) 4 (7.1) o0.001
Hepatomegaly 12 (37.5) 4 (7.1) o0.001
Splenomegaly 9 (28.1) 3 (5.4) 0.007
Liver damage 2 (6.2) 8 (14.3) 0.318
Jaundice 11 (34.4) 15 (26.8) 0.469
Petechiae/purpura 10 (31.2) 2 (3.4) o0.001
Pneumonia 3 (9.4) 12 (21.4) 0.237
Congenital heart disease 0 (0) 3 (5.4) 0.550
Total 32 (100) 56 (100)
p-values were determined by the Fisher exact test.
a Other hematological disorders (neutropenia, leukocytosis, and thrombocytosis).
b Neurological dysfunction (tremor, hypotonia, and poor sucking reﬂex).
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ranged from 0 to 5.2105 copies/mL (median 4.55103 copies/
mL) in newborns and from 0 to 1.46105 copies/mL (median
1.35102 copies/mL) in infants (p40.05) (Fig. 1B). Unfortunately,
due to the limited availability of blood from newborns, viremia
was determined in only a few patients. The median HCMV
DNA concentrations in postnatal infection were higher in whole
blood samples from adult patients (1.24103 copies/mL; range
1.02102–6.85105 copies/mL) than infants (p¼0.01). In addi-
tion, we examined the HCMV level in infants without amplifying
of the UL146 and UL147 genes, and we found no differences in
viral load between the infant groups with and without successful
ampliﬁcation.
Prevalence of vCXCL genotypes
The HCMV genotypes detected in congenital and postnatal
infections in babies were compared with those identiﬁed from
adult patients in the same region. Phylogenetic analysis clustered
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Fig. 1. HCMV load in urine (A) and whole blood (B) samples from congenitally and postnatally infected patients. Bars in the box plots represent median viral loads, upper and
lower borders represent the 25th and 75th percentiles, and whiskers represent the minimum to maximum values. Bars in the scatter dot plot represent the mean viral loads.
The difference between the viral loads between the selected patient groups was statistically signiﬁcant (po0.05, Mann–Whitney test).
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the obtained isolates into ten distinct groups/genotypes: G1, G2,
G5, G7–G10, and G12–G14 according to Dolan et al. (2004).
Sequence analysis of vCXCL-1 revealed that the G1 and G8
genotypes contained the ELRCRC motif, G2 contained the ELRCKC
motif, and genotypes G7, G9, G10, G12–G14 contained the ELRCPC
motif (Fig. 2A). The strains belonging to genotype G5 contained the
CXC motif but lacked the ELR motif. Newborns with congenital
infection were most commonly infected with genotypes G1, G7,
and G5 of HCMV (Table 2, Fig. 2). The G1 genotype was detected in
almost one in three newborns (31.2%) and caused congenital
infection more frequently than infection in adults (p¼0.007).
Approximately 20% of newborns were infected with HCMV geno-
types G7 or G5. Genotypes G2, G8, G9, G12, and G13 each occurred
in only a small number of patients. Infants and adults were
usually infected with G7 and/or G5 virus genotype(s), and the
G7 genotype was the most prevalent, occurring in 19/56 (33.9%)
infants and 18/28 (64.3%) adults. The viral strains belonging to the
G5 genotype were detected in 19.7% of infants and in 42.8% of
adults. A comparison of the genotypic distribution in neonates
with those present in adults showed that the G7 and G5 genotypes
were found signiﬁcantly more often in the adult group than in the
congenital group (p¼0.001 and p¼0.042, respectively). Moreover,
these variants of the virus occurred twice as often in adults as in
infants (G7; p¼0.011 and G5; p¼0.037). The vCXCL-1 sequences
corresponding to groups G3, G4, G6, G14, and G15 were not found.
The statistical power was calculated to be 60–81% to detect
signiﬁcant differences in the G1 and G7 genotype distribution
between different patient groups, with statistical signiﬁcance at
α¼0.05.
The vCXCL-2 genotypic distribution was similar to the vCXCL-1
distribution in all patient groups. The prevalence of individual
UL147 genotypes in clinical isolates is shown in Table 2. Brieﬂy,
three main vCXCL-2 variants, G5, G1, and G7, were found in
congenital cases, whereas the G7 and G5 genotypes were pre-
valent in both infant and adult groups. An alignment of amino acid
sequences and phylogenetic trees for vCXCL-2 from newborns are
shown in Fig. 3. In approximately half of the adults (53.6%),
genotype G7 of the virus was found. This genotype was predomi-
nant in adults compared to neonates and infants (po0.001 and
p¼0.002, respectively). Another common HCMV genotype was
G13, which was detected in infants more frequently than in adults
(p¼0.026). Mixed infections with two HCMV strains were
detected in 4/56 (7.1%) infants and 3/28 (10.7%) adults. No mixed
infections were detected in congenital cases. The vCXCL genotype
Fig. 2. Amino acid alignments of vCXCL-1s from clinical isolates of newborns with congenital HCMV infection and the Towne and Davis reference strains. Consensus
sequences are shown at the bottom (A). UL146 gene fragment phylogenetic analysis in neonates with congenital HCMV infection (B). Urine (A), whole blood (B), and PBMC
(C) samples.
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distribution in postnatal infection was similar to those detected in
adult patients, and the G1 variant was more frequently found in
congenital HCMV infection.
The studied regions of the UL146 and UL147 genes showed a
high degree of variability. Our analysis revealed that the ratios of
sequence variability among different groups of UL146 ranged from
0.3% to 58.0% (mean 31%) at the DNA level and from 0.8% to 75%
(mean 42%) at the amino acid level. The overall variability of the
UL147 ORF was approximately 8.4% (range 0–14%) at the amino
acid level and was lower than that for the UL146 gene.
Linkage of UL146 and UL147 sequence genotypes
Potential linkage disequilibrium between both the UL146 and
UL147 genotypes was investigated in 123 isolates from children
and adults. The observation that 37 of 44 (84.1%) UL146 G7 were
UL147 G7's and that 23 of 29 (79.3%) UL146 G5 isolates were UL147
G5's shows a linkage between UL146 and UL147 genotypes
(Table 3). In all patients examined we observed a conformity
between UL146 and UL147 variants in 79.4% of the samples
(Cohen's kappa coefﬁcient ĸ¼0.794; po0.001). In the group of
children, compatibility in 77.8% of the samples was found (ĸ¼
0.778; po0.001).
Relationship between genotype, viral load, and clinical outcome
The symptoms and speciﬁc vCXCL-1 and vCXCL-2 genotypes
are presented in Tables 4 and 5, respectively. Analysis of infants
with symptomatic HCMV infection demonstrated that the G1, G7,
and G5 genotypes were common. Among infants infected by the
HCMV G1 genotype, the rates of CNS damage (11/18 cases; 61.1%)
and hepatomegaly (7/17 cases; 38.9%) were higher than in those
infected by other genotypes (p¼0.025 and p¼0.035, respectively).
The G1 genotype was associated with at least a 3-fold increased
risk of CNS damage in an unadjusted and adjusted model
(p¼0.036 and p¼0.027, respectively) and a 4-fold increased risk
of hepatomegaly (p¼0.015 and p¼0.010, respectively) (Table 6).
The risk of pneumonia was more than 3-fold higher following
infection with the G7 variant, while other symptoms including
IUGR and petechiae occurred more frequently in children infected
with the HCMV G12 (Table 6). A signiﬁcant relationship between
the genotype and level of HCMV DNA was detected. The viral load
in the urine samples was lower in children infected with HCMV
genotype G5 (po0.001) compared with those infected with other
HCMV genotypes (Fig. 4). Alternatively, high viruria levels were
correlated with the presence of the G9 genotype (po0.05),
although this variant was observed in only a small number of
children. As expected, a signiﬁcant association between viral loads
in the urine of children with congenital infection and HCMV
clinical sequelae was observed for microcephaly, splenomegaly
(p¼0.021), and neurological dysfunction (p¼0.049). The analysis
demonstrated an association between the viral loads in the
urine samples and the following symptoms in infants: CNS
damage (po0.05), neurological disorders (p¼0.024), hepatome-
galy (p¼0.011), splenomegaly (p¼0.009), SNHL (p¼0.014), and
thrombocytopenia (p¼0.011).
Discussion
Our study focused on genotype analysis of the vCXCL-1 and
vCXCL-2 genes and the distribution of speciﬁc genotypes in infants
with symptomatic HCMV infection. Different vCXCL genotypes
were transmitted during intrauterine and postnatal infection,
with a prevalence of the G7, G1, and G5 genotypes. We determined
that the viral load is associated with speciﬁc clinical sequelae
following HCMV infection. In addition, the G1 genotype seemed to
be assigned to a particular clinical outcome in infants, such as CNS
damage and hepatomegaly. This implies that different viral factors
could determine the pathology of HCMV infection in infants
The link between the UL146 clades and congenital infection has
been studied previously by several groups (Arav-Boger et al., 2005,
2006a; Dolan et al., 2004; Hassan-Walker et al., 2004; Heo et al.,
2008; Lurain et al., 2006). Molecular epidemiology studies based
on the UL146 gene were carried out in Asian (Aguayo et al. 2010;
Bradley et al., 2008; He et al., 2006), European, African, and
Australian populations (Bradley et al., 2008). In the study by
Bradley et al. (2008), genotype G7 (20%) and genotypes G13,
G12, G9, G1, and G2 were dominant in European samples. Because
we observed a similar genotype distribution in infants and adult
groups, we suggest that the G7, G5, and G1 genotypes are also
more prevalent in Central Poland. In the above-mentioned reports,
G2 and G1 were the predominant genotypes in Chinese children
(He et al., 2006), and G1 was the predominant genotype in
Japanese children with congenital HCMV infection (Aguayo et al.,
2010). Other genotypes, G13, G8, and G11, were dominant among
clinical isolates of congenital infection from United States (Heo
et al., 2008). Such a discrepancy could be due to differences in the
geographical distribution of the strains. It appears that the local
incidence of individual genotypes is different, but most genotypes
are probably distributed worldwide. Because various vCXCL-1
genotypes were detected in children infected congenitally, we
concluded that all genotypes could be transmissible from mother
to child. This observation is consistent with results concerning
other HCMV genes (Arav-Boger et al., 2006b; Paradowska et al.,
2013; Picone et al., 2005; Pignatelli et al., 2010; Waters et al.,
2010).
Table 2
Distribution of vCXCL genotypes in HCMV-infected patients.
Genotype Prevalence of vCXCL genotypes in patients No. of cases (%)
Newborns Infants Adults
vCXCL-1
G1 10 (31.2) 6 (10.7) 1 (3.6)
G2 1 (3.1) 1 (1.8) 0
G5 6 (18.8) 9 (16.1) 9 (32.1)
G7 7 (21.9) 16 (28.6) 15 (53.6)
G8 1 (3.1) 4 (7.1) 0
G9 3 (9.4) 3 (5.4) 0
G10 0 4 (7.1) 0
G12 3 (9.4) 2 (3.6) 0
G13 1 (3.1) 7 (12.5) 0
G14 0 0 0
G1/G7 0 2 (3.6) 0
G5/G7 0 1 (1.8) 3 (10.7)
G5/G8 0 1 (1.8) 0
G7/G12 0 0 0
vCXCL-2
G1 5 (15.6) 5 (8.9) 1 (3.6)
G2 2 (6.3) 2 (3.6) 0
G5 6 (18.8) 9 (16.1) 9 (32.1)
G7 5 (15.6) 11 (19.6) 15 (53.6)
G8 4 (12.5) 5 (8.9) 0
G9 4 (12.5) 3 (5.4) 0
G10 1 (3.1) 5 (8.9) 0
G12 3 (9.4) 2 (3.6) 0
G13 1 (3.1) 9 (16.1) 0
G14 1 (3.1) 0 0
G1/G7 0 1(1.8) 0
G5/G7 0 2 (3.6) 3 (10.7)
G5/G8 0 1 (1.8) 0
G7/G12 0 1 (1.8) 0
No. of patients 32 56 28
No. of isolates 33 65 35
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We found a strong correlation between the UL146 and UL147
genotypes (po0.001). A phylogenetic linkage between them was
found previously by Arav-Boger et al. (2006a), although no
interstrain recombination was shown within this region (Lurain
et al., 2006). Genotype analysis in the vCXCL region found co-
infections with multiple HCMV strains in congenitally infected
neonates (Arav-Boger et al., 2006a), postnatally infected children
(Heo et al., 2008), and transplant patients (Lurain et al., 2006).
Infection with multiple HCMV strains occurs in infants with
congenital HCMV infection and various genomic variants are
Fig. 3. Amino acid alignments (A) and phylogenetic analysis (B) of vCXCL-2 in clinical isolates obtained from neonates with congenital HCMV infection. Abbreviations are the
same as those in Fig. 2.
Table 3
Analysis of linkage disequilibrium.
UL146 UL147 genotype
genotype G1 G2 G5 G7 G8 G9 G10 G12 G13 G14 Total
G1 12 0 0 0 4 1 1 1 0 0 19
G2 0 2 0 0 0 0 0 0 0 0 2
G5 0 2 23 1 0 0 1 1 1 0 29
G7 0 1 4 37 0 0 0 0 1 1 44
G8 0 0 0 0 6 0 0 0 0 0 6
G9 0 0 0 0 0 6 0 0 0 0 6
G10 0 0 0 0 0 0 4 0 0 0 4
G12 0 0 0 0 0 0 0 5 0 0 5
G13 0 0 0 0 0 0 0 0 8 0 8
G14 0 0 0 0 0 0 0 0 0 0 0
Total 12 5 27 38 10 7 6 7 10 1 123
The numbers indicate the quantity of patients (children and adults). Mixed HCMV
infections were included in the analysis. A signiﬁcant linkage between the UL146
and UL147 genotypes was found using Cohen's Kappa test (ĸ¼0.794, po0.001).
Table 4
Clinical ﬁndings at birth in newborns with congenital HCMV infection according to
the vCXCL-1 genotype distribution.
Symptoms Number of patients with vCXCL-1 genotypes
G1 G2 G5 G7 G8 G9 G12 G13 Total
Hematological disordersa 9 1 6 6 0 3 3 0 28
Neurological dysfunctionb 7 1 4 5 0 3 2 0 22
CNS damagec 8 1 2 3 0 3 2 1 20
Psychomotor retardation 7 1 3 2 0 3 1 0 17
Hearing loss 4 0 4 3 0 2 1 0 14
IUGR 6 0 2 4 0 0 2 0 14
Hepatomegaly 6 1 2 3 0 0 0 0 12
Jaundice 4 0 4 3 0 0 0 0 11
Ocular defects 2 0 3 2 1 2 1 0 11
Petechiae/purpura 3 0 1 4 0 0 1 1 10
Total 10 1 6 7 1 3 3 1 32
a Hematological disorders (anemia, thrombocytopenia, neutropenia, leukocy-
tosis, and thrombocytosis).
b Neurological dysfunction (tremor, hypotonia, and poor sucking reﬂex).
c CNS damage (intracranial calciﬁcation, cystic lesions, ventriculomegaly, and
microcephaly).
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found in different compartments (Pati et al., 2013; Ross et al.,
2011). We found mixed HCMV infections in approximately 7% of
children with postnatal infection and 11% of adults. Although we
did not detect mixed infections in newborns and the majority of
infants, we could not exclude the possibility that some of the
children might have had additional genotype variants due to
limitations of the genotyping method and sequencing of the
obtained PCR products. In addition, several samples failed to yield
products from either gene. The absence of the UL146 gene in DNA
isolates derived from different clinical samples of HCMV-infected
patients was also described by Bradley et al. (2008). We supposed
that not all genotypes were detected because primers were chosen
on the basis of alignments of available sequences. The results of
PCR sequencing depend on the original number of viral DNA
copies and can select only one of the multiple strains that are
potentially present in the original sample. In addition, PCR has
limitations, particularly those that result in biases in the template
to product ratios of the target sequences that are ampliﬁed during
PCR. The value of such data sets should be considered in relation to
the speciﬁcity of the primer (and probes) used in the ampliﬁcation
and with respect to the instrument, user and experimental
variability.
No speciﬁc UL146 genotype has been associated with outcome
thus far (Arav-Boger et al., 2006a). Dolan et al. (2004) and Hassan-
Walker et al. (2004) could not draw a direct link between
genotypes and symptoms due to small sample sizes. Heo et al.
(2008) found that UL146 genotypes did not correlate with symp-
tomatic births, and the three genotypes (G8, G10, and G12) that
they analyzed resulted in primarily asymptomatic infections. Our
results revealed that symptomatic infections in infants associated
with CNS damage or hepatomegaly were most commonly caused
by the HCMV G1 genotype. However, this observation must be
handled with caution before implementation of the functional
characterization of the vCXCL-1 variants. All of the examined
neonates who were born with symptomatic infection demon-
strated serious symptoms due to selection bias. Our data showed
that hematological disorders were most prevalent in newborns
with congenital HCMV infection, followed by neurological dys-
function and CNS damage. We observed that cytomegalic symp-
toms in the examined children were dependent more on the viral
load than on the vCXCL genotype. Therefore, the increased virus
burden and viral replication in affected organ systems might play
an important role in the pathogenesis of congenital cytomegaly. In
our studies, the viral load in urine was signiﬁcantly higher in
newborns with congenital HCMV infection than in infants with
postnatal infection. This observation agrees with previous results
showing that high viral loads in blood and urine of infants
correlate with congenital HCMV infection (Nijman et al., 2012).
In different sample populations of congenitally infected children, a
higher viral load at birth was consistently associated with an
elevated risk of SNHL (Boppana et al., 2005; Cannon et al., 2011). A
systemic virus burden was also shown to predict HCMV disease in
immunocompromised patients (Spector et al., 1999). The viral load
in amniotic ﬂuid is a prognostic factor of intrauterine transmission
and symptomatic infection in children (Guerra et al., 2000). Infants
with symptomatic infection exhibit higher urine and blood viral
loads than those with asymptomatic infection (Boppana et al.,
2005). In this study, we found an association between the viruria
level in infants and speciﬁc clinical ﬁndings.
HCMV has evolved mechanisms that allow it to spread
throughout the infected organism and evade the host immune
response control. One viral anti-cytokine mechanism is the pro-
duction of viral molecules that mimic chemokines or their recep-
tors. The vCXCL-1 protein contains from 115 to 121 amino acids,
and the vCXCL-2 protein is composed of 157–167 amino acids. It is
not clear whether vCXCL genotypes may be classiﬁed according to
their functional properties. In volunteers testing new vaccines
in vivo, the illnesses suffered during infection with individual
genotypes were different (Plotkin et al., 1989). The Toledo strain
is more virulent than the Towne strain and induces febrile illness
at a tenfold lower dose. Because the UL146 gene is signiﬁcantly
different in both strains, vCXCL-1 may be associated with HCMV
pathogenesis. vCXCL-2 variability is limited to the signal sequence,
which is cleaved during protein maturation (Arav-Boger et al.,
2005; Heo et al., 2008). Hassan-Walker et al. (2004) observed that
the majority of clinical strains obtained from transplant recipients
and infants with suspected congenital infection maintained the
conserved glutamic acid-leucine-arginine (ELR)CXC motif present
in the Toledo strain. This motif is present in 13 xCXCL-1 genotypes
and is necessary for chemokine activity, receptor binding, and
activation (Lurain et al., 2006). The ELRCXC motif also plays an
important role in angiogenesis (Strieter et al., 2005). Two vCXCL-1
genotypes (G5 and G6) lacking this motif contain a NGRCXC motif
that may act on T and B cells (Baggiolini et al., 1997). Conservation
Table 5
Clinical ﬁndings in infants with postnatal HCMV infection according to the vCXCL-1
genotype distribution.
Symptoms Number of patients with vCXCL-1 genotypes
G1 G2 G5 G7 G8 G9 G10 G12 G13 Mixed Total
Hematological
disordersa
5 1 6 8 4 3 1 2 3 2 35
Neurological
dysfunctionb
3 0 3 6 2 1 3 1 3 3 25
Psychomotor
retardation
3 0 3 5 2 1 2 1 1 2 20
Jaundice 1 0 1 6 2 1 0 2 2 0 15
Pneumonia 1 0 0 5 0 1 0 1 2 2 12
CNS damagec 2 0 2 1 0 1 1 0 1 2 10
Total 6 1 9 16 4 3 4 2 7 4 56
a Abbreviations are the same as those in Table 4.
b Abbreviations are the same as those in Table 4.
c Abbreviations are the same as those in Table 4.
Table 6
Assessment of the vCXCL-1 genotypes as prognostic variables for risk of cytomegaly symptoms in children.
Symptoms Genotype n (%) Unadjusted Adjusteda
p OR (95% CI) p OR (95% CI)
CNS damage G1 10/20 (50.0) 0.036 3.1 (1.1–9.1) 0.027 3.9 (1.1–10.0)
Hepatomegaly G1 7/16 (43.8) 0.015 4.3 (1.3–14.0) 0.010 4.9 (1.5–16.5)
Pneumonitis G7 8/15 (53.3) 0.032 3.5 (1.1–11.0) 0.054 3.5 (1.0–10.8)
Petechiae/purpura G12 3/12 (25.0) 0.010 12.3 (1.8–84.0) 0.017 11.6 (1.6–85.8)
IUGR G12 3/18 (16.7) 0.045 6.8 (1.0–44.3) 0.054 6.4 (1.0–42.4)
n: number of cases with the vCXCL-1 genotype among symptomatic patients; OR: odds ratio; 95% CI: 95% conﬁdence interval.
a Adjusted analysis was carried out for HCMV DNA copy number.
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of the chemokine motif in the UL146 protein suggests that this
gene region is biologically important for the virus. Modiﬁcation of
the ELR to the NGR motif could affect the chemokine function. The
evidence for this hypothesis can be observed in the relationship
between the G5 genotype, the NGRCXC motif, and a low viral load
in urine samples. All strains detected in our study, except
those corresponding to group G5, exhibited a conserved ELRCXC
domain. Similarly, in other studies, no association between vCXCL-
1 variants and the outcome in children (Arav-Boger et al., 2006a;
Heo et al., 2008) or adult transplant patients (Hassan-Walker et al.,
2004) was found.
Regardless of whether the vCXCL genotypes of the virus
actually affect the prevalence of disease symptoms in children
infected with HCMV, Arav-Boger et al. (2005) observed that the
nucleotide diversity was signiﬁcantly greater in the UL146 gene
than in the UL147 gene. Variations were distributed throughout
the UL146 gene, while the nucleotide variations in the UL147 gene
were located mainly in a region corresponding to a possible signal
peptide sequence (the ﬁrst 40 amino acids). The mean number of
synonymous substitutions in both genes was signiﬁcantly greater
than that of non-synonymous substitutions (Arav-Boger et al.,
2005). They suggested that both genes are subject to purifying
selection, but functional constraints are greater in UL147. More-
over, intrastrain recombination between both genes may be a
mechanism for generating the variability. It is not clear whether
the vCXCL-1 and vCXCL-2 genotypes are linked with their func-
tional properties.
Although the UL146 gene is very variable, their sequences are
maintained stably within and between infected individuals
(Stanton et al., 2005). The sequences of individual strains were
found to be invariable throughout long-term propagation in vitro
and in vivo (Hassan-Walker et al., 2004; Heo et al., 2008; Lurain
et al., 2006). UL146 stability is maintained under different immu-
nological settings and in healthy immune defense, as observed in
different patients who received organs from one donor (Lurain
et al., 2006). Heo et al. (2008) detected no sequence changes in
urine samples isolated from immunocompetent children shedding
the virus over several years. Thus, the source of HCMV variability
remains unresolved. It is suggested that de novo mutations in a
new host and selection of a dominant genotype during mixed
HCMV infections are the reasons for virus polymorphism
(Renzette et al., 2011). The use of high-throughput sequencing in
a genome study of samples collected from congenitally infected
newborns showed a high level of intrahost variability and that
HCMV exists as a complex mixture of variants (Renzette et al.,
2011). In addition, it is not known whether the UL146 genotypes
vary in biological properties, and further studies to investigate this
question are needed.
In summary, in this report, we claim that the HCMV UL146 and
UL147 genes that were ampliﬁed from clinical isolates are poly-
morphic and linked. We determined the genotype distribu-
tion in children with symptomatic HCMV infection that was
acquired congenitally or postnatally. In addition, we determined
the HCMV genotypes that caused active infection in immunocom-
promised adult individuals. This study shows that speciﬁc vCXCL
genotypes do not correlate with congenital infection. However, the
G1 genotype seems to be related to some symptoms of HCMV
infection in infants. Further studies using larger patient groups as
well as functional characterization of the vCXCL variants are
needed to conﬁrm the obtained results.
Materials and methods
Patients and samples
Ethics approval for this study was obtained from the Children's
Memorial Health Institute (Warsaw, Poland), the Polish Mother's
Memorial Hospital (Lodz, Poland), and the Medical University
(Lodz) ethics commissions. Informed consent was obtained from
the parents of all children in accordance with the ethical standards
of the Declaration of Helsinki. From February 2008 through March
2011, 32 newborns and 51 infants at the Children's Memorial
Health Institute (Department of Clinical Microbiology and Immu-
nology) and 38 infants at the Polish Mother's Memorial Hospital
(3rd Department of Pediatrics) were found to be HCMV-positive.
In all examined children, HCMV infection was conﬁrmed on the
basis of HCMV DNA (UL55 gene) detection and the results of
serological assays. Serum samples of the infants were assessed for
anti-HCMV IgG and IgM antibodies with the use of ELISA AxSYM
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Fig. 4. Comparison of the HCMV loads with the distribution of selected vCXCL-1 genotypes in blood and urine samples from infants. Bars indicate the median values.
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CMV IgM and IgG (Abbott Laboratories, Abbott Park, IL) or CLIA
LIASON CMV IgM and IgG assays (DiaSorin, Sallugia, Italy). The
LIASON CMV IgG avidity assay was utilized to distinguish primary
from non-primary HCMV infection. One hundred and forty-six
clinical specimens were collected from 121 selected infants,
including 32 newborns (median age 8.5 days; range 3–28 days)
with congenital HCMV infection and 89 infants between 1 and 12
months of age (median age 2.5 months) with postnatal or
unproven congenital HCMV infection. The clinical specimens
included 99 urine and 47 whole blood samples. Congenital infec-
tion was conﬁrmed by the detection of HCMV DNA in the urine
within the ﬁrst 2 to 3 weeks of life. Because all 89 infants were
examined after that time, congenital acquisition could not be
excluded. Subsequent detection of HCMV DNA was classiﬁed as
postnatal HCMV infection. All examined children were sympto-
matic at birth (newborns) or during subsequent evaluation in
infancy due to selection bias. Children were classiﬁed as having
symptomatic infection when they had Z1 clinical or laboratory
ﬁndings, including anemia, jaundice, petechiae/purpura, thrombo-
cytopenia, IUGR, hepatosplenomegaly, CNS damage (e.g.,
intracranial calciﬁcation, cystic lesions, ventriculomegaly, and
microcephaly), sensorineural hearing loss (SNHL), neurological
dysfunction, and others. DNA isolates from whole blood and periph-
eral bloodmononuclear cells (PBMCs) samples from 28 adult patients
with HCMV infection archived during 2006 and 2008 were included
in the study. The adult group was selected based on the detection
HCMV DNA and speciﬁc antibodies in the blood samples. These
patients consisted of 14 HIV patients with a CD4 count o200/mm3
and 14 kidney transplant recipients who were identiﬁed in the same
area. No speciﬁc symptoms associated with HCMV infection were
found in adult patients when the samples were taken. Laboratory
personnel were blinded to the demographic characteristics and
clinical ﬁndings of the study subjects.
PBMCs were isolated from the whole blood obtained from infants
and adults. PBMCs were isolated by centrifugation of peripheral blood
in a Ficoll-PaquePLUS (Amersham Biosciences AB, Uppsala, Sweden)
gradient following the manufacturer's recommended protocol. Total
genomic DNA was isolated with a QIAamp Blood Mini Kit (Qiagen
GmbH, Hilden, Germany). The concentration and purity of DNA were
assessed using a NanoDrop 2000c UV–vis Spectrophotometer (Thermo
Scientiﬁc, Wilmington, DE).
PCR ampliﬁcation
Extracted DNA was ampliﬁed in 10 Taq Buffer, 2.5 mM
deoxynucleoside triphosphate, 10 mM of each primer, and 1 U of
Taq DNA polymerase (Fermentas, Glen Burnie, MD). The UL146 and
UL147 ORFs were ampliﬁed using the outer primers, forward (F),
50-GAACGATCTCGTCCGGTTC-30 and reverse (R), 50-GTCATGGACG-
CAGTTTTG-30 (Genomed, Warsaw, Poland) (Arav-Boger et al.,
2006a). Reaction mixtures underwent an initial 5 min at 94 1C,
followed by 30 cycles of 94 1C for 1 min, 57 1C for 1 min, and 72 1C
for 1 min. The 30 cycles were followed by a single extension cycle
at 72 1C for 3 min. In the heminested PCR (hnPCR), a fragment of
the UL146 gene was ampliﬁed using hn forward (F1), 50-CTAAAA-
GATGGACGGCTAGG-30, and R primers. The primers used for UL147
gene ampliﬁcation were hn forward (F2), 50-AATAGCCAG-
CACTTCCTG-30 and R primers. The hnPCR was used when the
product of the outsider primers was either negative or weak. The
conditions for hnPCRs with all primer sets were 94 1C for 5 min,
followed by 30 cycles at 94 1C for 1 min, 57 1C (UL146) or 53 1C
(UL147) for 30 s, and 72 1C for 1 min. The 30 cycles were followed
by a single extension cycle at 72 1C for 3 min. Positive and negative
controls were run with each reaction. DNA isolates from MRC-5
cells (ATCC CCL-171, American Type Culture Collection, Rockville,
MD) infected with HCMV strain Towne (ATCC VR-977) or Davis
(ATCC VR-807) were used as a positive control in all PCR runs, and
nuclease-free water was used as a negative control. All ampliﬁca-
tions were carried out with a Veriti 96 Well Thermal Cycler
(Applied Biosystems, Foster City, CA). The products were analyzed
using a QIAxcel DNA screening gel cartridge (Qiagen) on a QIAxcel
system, which enabled capillary electrophoresis. A 25–800 bp QX
DNA Size Marker (Qiagen) was included on QIAxcel runs, and
the product size was determined using Biocalculator software
(Qiagen).
HCMV genotyping and phylogenetic analysis
PCR products were sequenced using the MiSeq system (Illu-
mina, San Diego, CA), and analyzed with Chromas and BLAST
bioinformatics tools. The sequences obtained were aligned with
NCBI_BLAST software, and compared to reference sequences for
vCXCL-1 and vCXCL-2 genotypes (GeneBank accession numbers
AY446866, AY446868, AY446870, AY446877, AY446880, AY44-
6885, AY446887, AY446889, AY446890, AY446893, AY446894,
AY681092, AY681095, and DQ115754), and sequences from Dolan
et al. (2004) and Heo et al. (2008). The designated genotypic group
(G) numbers were assigned according to 15 groups described by
Heo et al. (2008), where G1 corresponded to group 1. The
phylogenetic analysis was conducted using CLC Workbench 4.03.
The phylogenetic tree for UL146 and UL147 was constructed by
using the Unweighted Pair Group Method (UPGMA), and included
the laboratory Towne and Davis HCMV strains.
HCMV quantiﬁcation by real-time PCR
HCMV DNA copy numbers were determined by real-time PCR
(Paradowska et al., 2006, 2012). The primer set located within the
UL55 gene and a TaqMan probe labeled at the 50 end with FAM (6-
carboxyﬂuoroscein) and at the 30 end with TAMRA (6-carboxyte-
tramethylrhodamine) were used (Hassan-Walker et al., 2001).
The primers (Genomed) and probe (Metabion International AG,
Martinsried, Germany) used were the following: primer gB1,
50-GAGGACAACGAAATCCTGTTGGGCA-30, primer gB2, 50-GTCGACG-
GTGGAGATACTGCTGAGG-30, and probe, 50-CAATCATGCGTTTGAA-
GAGGTAGTCCA-30. The real-time PCR was prepared in a volume of
25 mL containing 0.4 mM of each primer, 0.2 mM of the ﬂuorogenic
probe, TaqMan Universal PCR Master Mix (Applied Biosystems), and
5 mL of the DNA extract or calibrated plasmid dilution (standard
curve). Following activation for 10 min at 95 1C, 60 cycles of 15 s at
95 1C and 1 min at 60 1C were carried out in a 7900HT Fast Real-
Time PCR System (Applied Biosystems). Triplicate standards of
plasmid DNA containing the entire UL55 open reading frame, and
consisting of 1, 5, 10, 100, 1000, 10,000, and 100,000 copies were
included in each run (Temperton et al., 2003). The number of
target copies was determined from the threshold cycle CT. The
sensitivity of the assay has been determined to be approximately
200 copies/mL.
Statistical analysis
Genotype distributions and the relationship between genotype
and the outcome of HCMV infections were analyzed using Fisher's
exact and Chi-square tests. No prior sample size determination
was made due to the observational character of the present study.
A posthoc power calculation for unequal variances was performed.
Consistencies between genotypes were compared using Cohen's
Kappa coefﬁcient. To compare the viral load between the various
groups, a non-parametric Mann–Whitney U test was performed.
Logistic regression models were used to evaluate the association
between the virus genotype and symptoms. A p value of o0.05
was considered signiﬁcant. Statistical analysis was performed
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using the SPSS statistical software package for Windows 17.0
(SPSS, Chicago, IL) and Statistica 10.0 software (Stat Soft. Inc.,
Tulsa, OK).
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Memorial Health Institute, Warsaw), (The Children’s Memorial
Health Institute, Warsaw), Prof. Jan Kuydowicz, Dr. Elżbieta Jabło-
nowska, Dr. Ewa Małolepszy (Department of Infectious Diseases and
Hepatology, Medical University in Lodz), Dr. Zbigniew Zbróg and
Dr. Bożena Kaczmarek (Nephrology Department, N. Copernicus
Provincial Specialist Hospital, Lodz) for providing samples from
patients. We are grateful to John Blaho and M. Anna Kowalska for
valuable comments on the manuscript, and Przemysław Paradowski
for assistance in statistical analysis.
References
Aguayo, F., Murayama, T., Eizuru, Y., 2010. UL146 variability among clinical isolates
of human cytomegalovirus from Japan. Biol. Res. 43, 475–480 (doi: /S0716-
97602010000400013).
Akter, P., Cunningham, C., McSharry, B.P., Dolan, A., Addison, C., Dargan, D.J.,
Hassan-Walker, A.F., Emery, V.C., Grifﬁths, P.D., Wilkinson, G.W., Davison, A.J.,
2003. Two novel spliced genes in human cytomegalovirus. J. Gen. Virol. 84,
1117–1122.
Arav-Boger, R., Zong, J.C., Foster, C.B., 2005. Loss of linkage disequilibrium and
accelerated protein divergence in duplicated cytomegalovirus chemokine
genes. Virus Genes 31, 65–72.
Arav-Boger, R., Foster, C.B., Zong, J.C., Pass, R.F., 2006a. Human cytomegalovirus
encoded α-chemokines exhibit high seguence variability in congenitally
infected newborns. J. Infect. Dis. 193, 788–791.
Arav-Boger, R., Battaglia, C.A., Lazzarotto, T., Gabrielli, L., Zong, J.C., Hayward, G.S.,
Diener-West, M., Landini, M.P., 2006b. Cytomegalovirus (CMV)-encoded UL144
(truncated tumor necrosis factor receptor) and outcome of congenital CMV
infection. J. Infect. Dis. 194, 464–473.
Baggiolini, M., Dewald, B., Moser, B., 1997. Human chemokines, un update. Annu.
Rev. Immunol. 15, 675–705.
Barbi, M., Binda, S., Caroppo, S., Primache, V., Didò, P., Guidotti, P., Corbetta, C.,
Melotti, D., 2001. CMV gB genotypes and outcome of vertical transmission:
study on dried blood spots of congenitally infected babies. J. Clin. Virol. 21,
75–79.
Boppana, S.B., Fowler, K.B., Pass, R.F., Rivera, L.B., Bradford, R.D., Lakeman, F.D., Britt,
W.J., 2005. Congenital cytomegalovirus infection, association between virus
burden in infancy and hearing loss. J. Pediatr. 146, 817–823.
Bradley, A.J., Kovács, I.J., Gatherer, D., Dargan, D.J., Alkharsah, K.R., Chan, P.K.,
Carman, W.F., Dedicoat, M., Emery, V.C., Geddes, C.C., Gerna, G., Ben-Ismaeil, B.,
Kaye, S., McGregor, A., Moss, P.A., Pusztai, R., Rawlinson, W.D., Scott, G.M.,
Wilkinson, G.W., Schulz, T.F., Davison, A.J., 2008. Genotypic analysis of two
hypervariable human cytomegalovirus genes. J. Med. Virol. 80, 1615–1623,
http://dx.doi.org/10.1002/jmv.21241.
Bradley, A.J., Lurain, N.S., Ghazal, P., Trivedi, U., Cunningham, C., Baluchova, K.,
Gatherer, D., Wilkinson, G.W., Dargan, D.J., Davison, A.J., 2009. High-throughput
sequence analysis of variants of human cytomegalovirus strains Towne and
AD169. J. Gen. Virol. 90, 2375–2380, http://dx.doi.org/10.1099/vir.0.013250-0.
Cannon, M.J., Hyde, T.B., Schmid, D.S., 2011. Review of cytomegalovirus shedding in
bodily ﬂuids and relevance to congenital cytomegalovirus infection. Rev. Med.
Virol. 21, 240–255, http://dx.doi.org/10.1002/rmv.695.
Cha, T.A., Tom, E., Kemble, G.W., Duke, G.M., Mocarski, E.S., Spaete, R.R., 1996.
Human cytomegalovirus clinical isolates carry at least 19 genes not found in
laboratory strains. J. Virol. 70, 78–83.
Dolan, A., Cunningham, C., Hector, R.D., Hassan-Walker, A.F., Lee, L., Addison, C.,
Dargan, D.J., McGeoch, D.J., Gatherer, D., Emery, V.C., Grifﬁths, P.D., Sinzger, C.,
McSharry, B.P., Wilkinson, G.W., Davison, A.J., 2004. Genetic content of wild-
type human cytomegalovirus. J. Gen. Virol. 85, 1301–1312.
Dollard, S.C., Grosse, S.D., Ross, D.S., 2007. New estimates of the prevalence of
neurological and sensory sequelae and mortality associated with congenital
cytomegalovirus infection. Rev. Med. Virol. 17, 355–363.
Guerra, B., Lazzarotto, T., Quarta, S., Lanari, M., Bovicelli, L., Nicolosi, A., Landini, M.
P., 2000. Prenatal diagnosis of symptomatic congenital cytomegalovirus infec-
tion. Am. J. Obstet. Gynecol. 183, 476–482.
Hahn, G., Rose, D., Wagner, M., Rhiel, S., McVoy, M.A., 2003. Cloning of the genomes
of human cytomegalovirus strains Toledo, TownevarRIT3, and Townelong as
BACs and site-directed mutagenesis using a PCR-based technique. Virology 307,
164–177.
Hassan-Walker, A.F., Mattes, F.M., Grifﬁths, P.D., Emery, V.C., 2001. Quantity of
cytomegalovirus DNA in different leukocyte populations during active infection
in vivo and the presence of gB and UL18 transcripts. J. Med. Virol. 64, 283–289.
Hassan-Walker, A.F., Okwuadi, S., Lee, L., Grifﬁths, P.D., Emery, V.C., 2004. Sequence
variability of the α-chemokine UL146 from clinical strains of human cytome-
galovirus. J. Med. Virol. 74, 573–579.
He, R., Ruan, Q., Qi, Y., Ma, Y.P., Huang, Y.J., Sun, Z.R., Ji, Y.H., 2006. Sequence
variability of human cytomegalovirus UL146 and UL147 genes in low-passage
clinical isolates. Intervirology 49, 215–223.
He, R., Ma, Y., Qi, Y., Jiang, S., Wang, N., Li, M., Ji, Y., Sun, Z., Ruan, Q., 2012.
Characterization of human cytomegalovirus UL146 transcripts. Virus Res. 163,
223–228, http://dx.doi.org/10.1016/j.virusres.2011.09.034.
Heo, J., Petheram, S., Demmier, G., Murph, J.R., Adler, S.P., Bale, J., Sparer, T.E., 2008.
Polymorphism within human cytomegalovirus chemokine (UL146/UL147) and
cytokine receptor genes (UL144) are not predictive of sequelae in congenitally
infected children. Virology 378, 86–96, http://dx.doi.org/10.1016/j.virol.
2008.05.002.
Kenneson, A., Cannon, M.J., 2007. Review and meta-analysis of the epidemiology of
congenital cytomegalovirus (CMV). Rev. Med. Virol. 17, 253–276.
Lurain, N.S., Fox, A.M., Lichy, H.M., Bhorade, S.M., Ware, C.F., Huang, D.D., Kwan,
S.-P., Garrity, E.R., Chou, S., 2006. Analysis of the human cytomeaglovirus
genomic region from UL146 through UL147A reveals sequence hypervariability,
genotypic stability and overlapping transcripts. Virol. J. 3, 4.
Lüttichau, H.R., 2010. The cytomegalovirus UL146 gene product vCXCL1 targets both
CXCR1 and CXCR2 as an agonist. J. Biol. Chem. 285, 9137–9146, http://dx.doi.
org/10.1074/jbc.M109.002774.
Mocarski Jr., E.S., 2002. Immunomodulation by cytomegaloviruses, manipulative
strategies beyond evasion. Trends Microbiol. 10, 332–339.
Nijman, J., van Loon, A.M., de Vries, L.S., Koopman-Esseboom, C., Groenendaal, F.,
Uiterwaal, C.S., Verboon-Maciolek, M.A., 2012. Urine viral load and correlation
with disease severity in infants with congenital or postnatal cytomegalovirus
infection. J. Clin. Virol. 54, 121–124, http://dx.doi.org/10.1016/j.jcv.2012.02.017.
Paradowska, E., Przepiórkiewicz, M., Nowakowska, D., Studzińska, M., Wilczyński, J.,
Emery, V.C., Leśnikowski, Z.J., 2006. Detection of cytomegalovirus in human
placental cells by polymerase chain reaction. Acta Pathol. Microbiol. Immunol.
Scand. 114, 764–771.
Paradowska, E., Studzińska, M., Nowakowska, D., Wilczyński, J., Rycel, M., Suski, P.,
Gaj, Z., Kaczmarek, B., Zbróg, Z., Leśnikowski, Z.J., 2012. Distribution of UL144,
US28 and UL55 genotypes in Polish newborns with congenital cytomegalovirus
infections. Eur. J. Clin. Microbiol. Infect. Dis. 31, 1335–1345, http://dx.doi.org/
10.1007/s10096-011-1447-z.
Paradowska, E., Jabłońska, A., Studzińska, M., Suski, P., Kasztelewicz, B., Zawilińska,
B., Wiśniewska-Ligier, M., Dzierżanowska-Fangrat, K., Woźniakowska-Gęsicka,
T., Czech-Kowalska, J., Lipka, B., Kornacka, M., Pawlik, D., Tomasik, T., Kosz-
Vnenchak, M., Leśnikowski, Z.J., 2013. Distribution of cytomegalovirus gN
variants and associated clinical sequelae in infants. J. Clin. Virol. 58, 271–275,
http://dx.doi.org/10.1016/j.jcv.2013.05.024.
Paradowska, E., Jabłońska, A., Studzińska, M., Kasztelewicz, B., Zawilińska, B.,
Wiśniewska-Ligier, M., Dzierżanowska-Fangrat, K., Woźniakowska-Gęsicka, T.,
Kosz-Vnenchak, M., Leśnikowski, Z.J., 2014. Cytomegalovirus glycoprotein H
genotype distribution and the relationship with hearing loss in children. J. Med.
Virol. 86, 1421–1427, http://dx.doi.org/10.1002/jmv.23906.
Pati, S.K., Pinninti, S., Novak, Z., Chowdhury, N., Patro, R.K., Fowler, K., Ross, S.,
Boppana, S., 2013. NIDCD CHIMES Study Investigators, 2013. Genotypic diver-
sity and mixed infection in newborn disease and hearing loss in congenital
cytomegalovirus infection. Pediatr. Infect. Dis. J. 32, 1050–1054, http://dx.doi.
org/10.1097/INF.0b013e31829bb0b9.
Penfold, M.E., Dairaghi, D.J., Duke, G.M., Saederup, N., Mocarski, E.S., Kemble, G.W.,
Shall, T.J., 1999. Cytomegalovirus encodes a potent α-chemokine. Proc. Natl.
Acad. Sci. U. S. A. 96, 9839–9844.
Picone, O., Costa, J.M., Chaix, M.L., Ville, Y., Rouzioux, C., Leruez-Ville, M., 2005.
Human cytomegalovirus UL144 gene polymorphisms in congenital infections.
J. Clin. Microbiol. 43, 25–29.
Pignatelli, S., Dal Monte, P., Rossini, G., Landini, M.P., 2004. Genetic polymorphisms
among human cytomegalovirus (HCMV) wild-type strains. Rev. Med. Virol. 14,
383–410.
Pignatelli, S., Lazzarotto, T., Gatto, M.R., Dal Monte, P., Landini, M.P., Faldella, G.,
Lanari, M., 2010. Cytomegalovirus gN genotypes distribution among congeni-
tally infected newborns and their relationship with symptoms at birth and
sequelae. Clin. Infect. Dis. 1, 33–41, http://dx.doi.org/10.1086/653423.
Plotkin, S.A., Starr, S.E., Friedman, H.M., Gönczöl, E., Weibel, R.E., 1989. Protective
effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus
administered as a challenge. J. Infect. Dis. 159, 860–865.
Prichard, M.N., Penfold, M.E., Duke, G.M., Spaete, R.R., Kemble, G.W., 2001. A review
of genetic differences between limited and extensively passaged human
cytomegalovirus strains. Rev. Med. Virol. 11, 191–200.
Renzette, N., Bhattacharjee, B., Jensen, J.D., Gibson, L., Kowalik, T.F., 2011. Extensive
genome-wide variability of human cytomegalovirus in congenitally infected
infants. PLoS Pathog. 7, e1001344, http://dx.doi.org/10.1371/journal.ppat.1001344.
Ross, S.A., Novak, Z., Pati, S., Patro, R.K., Blumenthal, J., Danthuluri, V.R., Ahmed, A.,
Michaels, M.G., Sánchez, P.J., Bernstein, D.I., Tolan, R.W., Palmer, A.L., Britt, W.J.,
Fowler, K.B., Boppana, S.B., 2011. Mixed infection and strain diversity in
E. Paradowska et al. / Virology 462-463 (2014) 207–217216
congenital cytomegalovirus infection. J. Infect. Dis. 204, 1003–1007, http://dx.
doi.org/10.1093/infdis/jir457.
Spector, S.A., Hsia, K., Crager, M., Pilcher, M., Cabral, S., Stempien, M.J., 1999.
Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease
and survival in advanced AIDS. J. Virol. 73, 7027–7030.
Stagno, S., Pass, R.F., Dworsky, M.E., Henderson, R.E., Moore, E.G., Walton, P.D.,
Alford, C.A., 1982. Congenital cytomegalovirus infection, the relative impor-
tance of primary and recurrent maternal infection. N. Engl. J. Med. 306,
945–949.
Stanton, R., Westmoreland, D., Fox, J.D., Davison, A.J., Wilkinson, G.W., 2005.
Stability of human cytomegalovirus genotypes in persistently infected renal
transplant recipients. J. Med. Virol. 75, 42–46.
Strieter, R.M., Burdick, M.D., Gomperts, B.N., Belperio, J.A., Keane, M.P., 2005. CXC
chemokines in angiogenesis. Cytokine Growth Factor Rev. 16, 593–609.
Temperton, N.J., Quenelle, D.C., Lawson, K.M., Zuckerman, J.N., Kern, E.R., Grifﬁths, P.
D., Emery, V.C., 2003. Enhancement of humoral immune responses to a human
cytomegalovirus DNA vaccine, adjuvant effects of aluminum phosphate and
CpG oligodeoxynucleotides. J. Med. Virol. 70, 86–90.
Waters, A., Hassan, J., deGascun, C., Kissoon, G., Knowles, S., Molloy, E., Connell, J.,
Hall, W.W., 2010. Human cytomegalovirus UL144 is associated with viremia and
infant development sequelae in congenital infection. J. Clin. Microbiol. 48,
3956–3962, http://dx.doi.org/10.1128/JCM.01133-10.
E. Paradowska et al. / Virology 462-463 (2014) 207–217 217
